SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise ...
本文讲解如何利用本仓库提供的 Copilot 自定义指令（instructions/joyride-user-project.instructions.md），让 GitHub Copilot 化身为一名精通 ...
LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Replimune Group, Inc. (REPL) have opportunity to lead the securities fraud ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Программисты пишут свои вики в obsidian, в org файлах и других инструментах. С ними готовятся к собеседованию, ищут команды для баша, хранят ...
The White House pushed health officials to re-examine the Food and Drug Administration’s repeated rejections of an advanced melanoma medication from Replimune Group REPL-0.54%decrease; down pointing ...
Replimune Group REPL-0.69%decrease; down pointing triangle said Friday it has reached an agreement with the Food and Drug Administration on a path to resubmit its application for its experimental ...
Hosted on MSN
Wedbush downgrades Replimune Group (REPL)
Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...
In July 2025, REPL announced it had received a CRL for its biologics license application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who were PD-1 ...
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results